Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access Program. The company said it will expand the program, which is evaluating its investigative therapeutic intranasal foralumab, from 10 patients to 30.

Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Program

NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed its intranasal foralumab non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients.

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled additional positive results from its Expanded Access Program for patients with non-active secondary progressive multiple sclerosis (na-SPMS). The clinical-stage biopharmaceutical company said patients treated with its investigative therapeutic intranasal foralumab demonstrated multiple improvements, with 70% showing an improvement in fatigue after six months of follow-up.

Tiziana Life Sciences reports additional positive results from Multiple Sclerosis program

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients. The data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. Fatigue is a debilitating symptom for many MS patients and is measured by the Modified Fatigue Impact Scale (MFIS).

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its study on foralumab, the company's lead candidate, was published in Neurology Today, the esteemed news source of the American Academy of Neurology (AAN). The study sheds light on foralumab's potential in attenuating microglial activation in non-active secondary progressive multiple sclerosis (na-SPMS) patients with progression independent of relapse (PIRA).

Tiziana Life Sciences' foralumab study highlighted in Neurology Today

- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado -

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new quantitative PET imaging data on foralumab at the Annual Meeting of the American Academy of Neurology in Denver. The company presented data from its platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS.

Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS

Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from April 13 to 18 in Denver, Colorado. The company said the oral presentation, titled “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS,” will be part of the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session.

Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” that will be presented during the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session at the Annual Meeting of the American Academy of Neurology, to be held April 13-18, 2024 in Denver, Colorado.

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that chairman of its Scientific Advisory Board Dr. Howard Weiner will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in models of Alzheimer's and Parkinson's disease at an upcoming conference.

Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer's and Parkinson's disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Lisbon, Portugal.

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS).  The clinical-stage biopharmaceutical company said PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period.

Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patients

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024.

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead drug candidate, to further reduce system and vascular inflammation associated with Type 2 diabetes (T2D) and also in patients with non-T2D obesity. The company said that the patent application describes the potential for foralumab, which is a fully human anti-CD3 antibody, to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease when combined with a GLP-1ra in this patient population.

Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The trial involves six investigational centers which will recruit up to 18 patients per treatment arm.

Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis study

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).   Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient's everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images is an integral component of this study.

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana's recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS) and other neuroinflammatory and neurodegenerative diseases such as Alzheimer's disease.

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

Biotechnology firm Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it had successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women's Hospital, a key member of the Mass General Brigham Healthcare System Expanded Access (EA) Program. The news brings the total number of patients being followed in the EA Program to 10.

Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patients

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access (EA) Program. A total of ten patients are now being followed in the EA Program.

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer's. Tiziana's management will also be participating in one-on-one partnering meetings throughout the conference.

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023

Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA). Sign-off by the US Food & Drug Administration for this approach marks a major step forward in making treatment more accessible and convenient for those grappling with the debilitating condition.

Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatment

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis. The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences. Delivery Device Training materials have been developed and refined in collaboration with the FDA, and patients will be trained in the use of the nasal device in accordance with these materials.

News for Tiziana Life Sciences Ltd Stock (TLSA)